Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.54M Buy
10,103
+521
+5% +$112K 0.18% 128
2026
Q1
$1.89M Sell
9,582
-683
-7% -$152K 0.15% 141
2025
Q4
$2.35M Buy
10,265
+188
+2% +$42.8K 0.2% 116
2025
Q3
$2.33M Buy
10,077
+1,141
+13% +$232K 0.21% 119
2025
Q2
$1.66M Sell
8,936
-569
-6% -$106K 0.17% 133
2025
Q1
$1.99M Sell
9,505
-113
-1% -$22K 0.22% 104
2024
Q4
$1.71M Buy
9,618
+1,983
+26% +$365K 0.18% 125
2024
Q3
$1.51M Sell
7,635
-558
-7% -$104K 0.2% 128
2024
Q2
$1.41M Buy
8,193
+42
+0.5% +$6.96K 0.19% 130
2024
Q1
$1.48M Buy
8,151
+498
+7% +$85.8K 0.2% 126
2023
Q4
$1.19M Buy
7,653
+363
+5% +$52.9K 0.18% 143
2023
Q3
$1.09M Sell
7,290
-622
-8% -$91.3K 0.16% 155
2023
Q2
$1.07M Sell
7,912
-95
-1% -$13.9K 0.16% 161
2023
Q1
$1.28M Buy
+8,007
New +$1.22M 0.2% 133

Other funds holding ABBV

Nilsine Partners's ABBV Position: Q2 2026 in Review

Nilsine Partners increased its AbbVie (ABBV) stake by 5.4% in Q2 2026, buying an estimated $112K and bringing the position to 10,103 shares worth $2.54M. The position accounts for 0.18% of the portfolio, ranked #128.

Nilsine Partners first reported a position in ABBV in Q1 2023 and has held it in 14 quarters since. 1,476 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Nilsine Partners held 10,103 shares of AbbVie worth $2.54M as of Q2 2026.
  • Nilsine Partners bought 521 AbbVie shares in Q2 2026, an estimated $112K.
  • AbbVie made up 0.18% of Nilsine Partners's portfolio in Q2 2026, its #128 holding.
  • Nilsine Partners first reported a position in AbbVie in Q1 2023 and has held it in 14 quarters since.
  • 1,476 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Nilsine Partners's 13F filing for Q2 2026, filed 24 Jul 2026.